Figure 1 A-D

Figure 1A




Figure 1B




Figure 1C




Figure 1D




Figure 1 E-H

Figure 1E




Figure 1F




Figure 1G




Figure 1H





Figure 2A

Donor A



Donor B





Figure 2A (continued)

Donor C



Donor D





Figure 2B

Donor C - CD8



Donor C - NK




Figure 2B (continued)

Donor C - Vd1





Figure 2C

Donor A



Donor B





Figure 2C (continued)

Donor C



Donor D





Figure 2D

Donor C: CD8+ cells



Donor C: Vδ1 γδ T-cells




Figure 2D (continued)

Donor C: NK cells




Figure 3 A-D

Figure 3A




Figure 3B




Figure 3C




Figure 3D




Figure 3 E-H

Figure 3E




Figure 3F




Figure 3G




Figure 3H




Figure 3 I-L

Figure 3I




Figure 3J




Figure 3K




Figure 3L




Figure 3 M-P

Figure 3M




Figure 3N




Figure 3O




Figure 3P




Figure 4 A-B

Figure 4A




Figure 4B




Figure 4 C-D

Figure 4C




Figure 4D




Figure 4 E-F

Figure 4E




Figure 4F




Figure 4 G-H

Figure 4G




Figure 4H




Figure 5 A-B

Figure 5A




Figure 5B




Figure 5 C-D

Figure 5C




Figure 5D




Figure 5 E-F

Figure 5E




Figure 5F




Figure 6 A-D




Figure 7A



Controls
Survival (%)
140
120
100
80
60
40
20
0
0.0001
0.01
1
100
10000
Concentration (nM)
duocarmycin type toxin
Zoledronate
HMBPP
XC1
XD1
pAg conjugates (1)
Survival (%)
140
120
100
80
60
40
20
0
0.0001
0.001
0.01
0.1
1
10
Concentration (µg/mL)
Rituximab
ADC-XC4-r
ADC-XD4-r
ADC-XD13-r
ADC-XC4-i
ADC-XD4-i
ADC-XD13-i

Figure 7A (continued)




Figure 7B



pAg conjugates overview % survival at 10 µg/mL
Survival (%)
120
100
80
60
40
20
0
Rituximab
Isotype control
ADC-XC4-r
ADC-XD13-r
ADC-XD4-r
ADC-XD13-i
ADC-XD4-i
ADC-XC4-i
ADC-XS2-r
ADC-XD18-r
ADC-XC9-r
ADC-XC13-r
ADC-XS2-i
ADC-XD18-i
ADC-XC9-i
ADC-XC13-i
ADC-XS7-r
ADC-XS12-r
ADC-XS17-r
ADC-XS22-r
ADC-XS7-i
ADC-XS12-i
ADC-XS17-i
ADC-XS22-i

Figure 8



Vδ2 - CD107a
Donor A-1
% activated cells
100
80
60
40
20
0
0.000001
0.00001
0.0001
0.001
0.01
0.1
1
10
100
1000
Concentration (µg/mL)
ADC-XC4-r
ADC-XC4-i
ADC-XD4-r
ADC-XD4-i
ADC-XD13-r
ADC-XD13-i
Rituximab
Vδ2 - CD107a
Donor B
% activated cells
100
80
60
40
20
0
0.000001
0.00001
0.0001
0.001
0.01
0.1
1
10
100
1000
Concentration (µg/mL)
ADC-XC4-r
ADC-XC4-i
ADC-XD4-r
ADC-XD4-i
Rituximab

Figure 8 (continued)





Figure 8 (continued)






Figure 8 (continued)




Figure 8 (continued)




Figure 8 (continued)




Figure 8 (continued)




Figure 8 (continued)





Figure 8 (continued)







Figure 8 (continued)







Figure 8 (continued)






Figure 9A



CD107a EC50 summary
#
10
1
0.1
0.01
0.001
EC50 (µg/mL)
Rituximab
ADC-XC4-r
ADC-XD13-r
ADC-XD4-r
ADC-XS2-r
ADC-XD18-r
ADC-XC9-r
ADC-XC13-r
ADC-XS7-r
ADC-XS12-r
ADC-XS17-r
ADC-XD24-r
ADC-XS22-r
ADC-XS25-r
ADC-XD65-r
ADC-XD44-r
ADC-XD45-r
ADC-XD46-r
ADC-XD58-r
ADC-XD63-r
EC50 value > geomean EC50 value of rituximab
and no full DRC / no activity

Figure 9B



IFNγ EC50 summary
#
10
1
0.1
0.01
0.001
EC50 (µg/mL)
Rituximab
ADC-XC4-r
ADC-XD13-r
ADC-XD4-r
ADC-XS2-r
ADC-XD18-r
ADC-XC9-r
ADC-XC13-r
ADC-XS7-r
ADC-XS12-r
ADC-XS17-r
ADC-XD24-r
ADC-XS22-r
ADC-XS25-r
ADC-XD65-r
ADC-XD44-r
ADC-XD45-r
ADC-XD46-r
ADC-XD58-r
ADC-XD63-r
EC50 value > geomean EC50 value of rituximab
and no full DRC / no activity

Figure 9C



TNFα EC50 summary
EC50 (µg/mL)
#
10
1
0.1
0.01
0.001
Rituximab
ADC-XC4-r
ADC-XD13-r
ADC-XD4-r
ADC-XS2-r
ADC-XD18-r
ADC-XC9-r
ADC-XC13-r
ADC-XS7-r
ADC-XS12-r
ADC-XS17-r
ADC-XD24-r
ADC-XS22-r
ADC-XS25-r
ADC-XD65-r
ADC-XD44-r
ADC-XD45-r
ADC-XD46-r
ADC-XD58-r
ADC-XD63-r
EC50 value > geomean EC50 value of rituximab
and no full DRC / no activity

Figure 9D



CD107a % activated Vδ2 γδ T cells summary
% activated Vδ2 γδ T cells
100
90
80
70
60
50
40
30
20
10
0
Rituximab
ADC-XC4-r
ADC-XD13-r
ADC-XD4-r
ADC-XS2-r
ADC-XD18-r
ADC-XC9-r
ADC-XC13-r
ADC-XS7-r
ADC-XS12-r
ADC-XS17-r
ADC-XD24-r
ADC-XS22-r
ADC-XS25-r
ADC-XD65-r
ADC-XD44-r
ADC-XD45-r
ADC-XD46-r
ADC-XD58-r
ADC-XD63-r
% activated cells > mean % activated cells of rituximab

Figure 9E



IFNγ % activated Vδ2 γδ T cells summary
% activated Vδ2 γδ T cells
100
90
80
70
60
50
40
30
20
10
0
Rituximab
ADC-XC4-r
ADC-XD13-r
ADC-XD4-r
ADC-XS2-r
ADC-XD18-r
ADC-XC9-r
ADC-XC13-r
ADC-XS7-r
ADC-XS12-r
ADC-XS17-r
ADC-XD24-r
ADC-XS22-r
ADC-XS25-r
ADC-XD65-r
ADC-XD44-r
ADC-XD45-r
ADC-XD46-r
ADC-XD58-r
ADC-XD63-r
% activated cells > mean % activated cells of rituximab

Figure 9F



TNFα % activated Vδ2 γδ T cells summary
% activated Vδ2 γδ T cells
100
90
80
70
60
50
40
30
20
10
0
Rituximab
ADC-XC4-r
ADC-XD13-r
ADC-XD4-r
ADC-XS2-r
ADC-XD18-r
ADC-XC9-r
ADC-XC13-r
ADC-XS7-r
ADC-XS12-r
ADC-XS17-r
ADC-XD24-r
ADC-XS22-r
ADC-XS25-r
ADC-XD65-r
ADC-XD44-r
ADC-XD45-r
ADC-XD46-r
ADC-XD58-r
ADC-XD63-r
% activated cells > mean % activated cells of rituximab

Figure 9G



CD107a MFI Vδ2 γδ T cells summary
CD107a MFI
15000
10000
5000
0
Rituximab
ADC-XC4-r
ADC-XD13-r
ADC-XD4-r
ADC-XS2-r
ADC-XD18-r
ADC-XC9-r
ADC-XC13-r
ADC-XS7-r
ADC-XS12-r
ADC-XS17-r
ADC-XD24-r
ADC-XS22-r
ADC-XS25-r
ADC-XD65-r
ADC-XD44-r
ADC-XD45-r
ADC-XD46-r
ADC-XD58-r
ADC-XD63-r
MFI > mean MFI of rituximab

Figure 9H



IFNγ MFI Vδ2 γδ T cells summary
IFNγ MFI
15000
10000
5000
0
Rituximab
ADC-XC4-r
ADC-XD13-r
ADC-XD4-r
ADC-XS2-r
ADC-XD18-r
ADC-XC9-r
ADC-XC13-r
ADC-XS7-r
ADC-XS12-r
ADC-XS17-r
ADC-XD24-r
ADC-XS22-r
ADC-XS25-r
ADC-XD65-r
ADC-XD44-r
ADC-XD45-r
ADC-XD46-r
ADC-XD58-r
ADC-XD63-r
MFI > mean MFI of rituximab

Figure 9I



TNFα MFI Vδ2 γδ T cells summary
TNFα MFI
20000
15000
10000
5000
0
Rituximab
ADC-XC4-r
ADC-XD13-r
ADC-XD4-r
ADC-XS2-r
ADC-XD18-r
ADC-XC9-r
ADC-XC13-r
ADC-XS7-r
ADC-XS12-r
ADC-XS17-r
ADC-XD24-r
ADC-XS22-r
ADC-XS25-r
ADC-XD65-r
ADC-XD44-r
ADC-XD45-r
ADC-XD46-r
ADC-XD58-r
ADC-XD63-r
MFI > mean MFI of rituximab

Figure 10A



CD107a vs IFNγ geomean EC50 summary
IFNγ geomean EC50 (µg/mL)
CD107a geomean EC50 (µg/mL)
0.01
0.1
1
10
#
*
ADC-XC4-r
ADC-XD13-r
ADC-XD4-r
ADC-XS2-r
ADC-XD18-r
ADC-XC9-r
ADC-XC13-r
ADC-XS7-r
ADC-XS12-r
ADC-XS17-r
ADC-XD24-r
ADC-XS22-r
ADC-XS25-r
ADC-XD65-r
ADC-XD44-r
ADC-XD45-r
ADC-XD46-r
ADC-XD58-r
ADC-XD63-r
Rituximab
and no full DRC / no activity

Figure 10B



CD107a vs IFNγ % Efficacy summary
Mean % activated Vδ2 γδ T cells (IFNγ)
Mean % activated Vδ2 γδ T cells (CD107a)
0
20
40
60
80
100
ADC-XC4-r
ADC-XD13-r
ADC-XD4-r
ADC-XS2-r
ADC-XD18-r
ADC-XC9-r
ADC-XC13-r
ADC-XS7-r
ADC-XS12-r
ADC-XS17-r
ADC-XD24-r
ADC-XS22-r
ADC-XS25-r
ADC-XD65-r
ADC-XD44-r
ADC-XD45-r
ADC-XD46-r
ADC-XD58-r
ADC-XD63-r
Rituximab

Figure 10C



CD107a vs IFNγ MFI summary
Mean IFNγ MFI
Mean CD107a MFI
15000
10000
5000
0
0
5000
10000
15000
ADC-XC4-r
ADC-XD13-r
ADC-XD4-r
ADC-XS2-r
ADC-XD18-r
ADC-XC9-r
ADC-XC13-r
ADC-XS7-r
ADC-XS12-r
ADC-XS17-r
ADC-XD24-r
ADC-XS22-r
ADC-XS25-r
ADC-XD65-r
ADC-XD44-r
ADC-XD45-r
ADC-XD46-r
ADC-XD58-r
ADC-XD63-r
Rituximab

Figure 11A



CD107a EC50 summary DAR2 versus DAR8
#
10
1
0.1
0.01
0.001
EC50 (µg/mL)
ADC-XD65-r
ADC8-XD65-r
Rituximab
Donor O
Donor A-2
and no full DRC / no activity

Figure 11B



IFNγ EC50 summary DAR2 versus DAR8
#
10
1
0.1
0.01
0.001
EC50 (µg/mL)
ADC-XD65-r
ADC8-XD65-r
Rituximab
Donor O
Donor A-2
and no full DRC / no activity

Figure 11C



TNFα EC50 summary DAR2 versus DAR8
#
10
1
0.1
0.01
0.001
EC50 (µg/mL)
ADC-XD65-r
ADC8-XD65-r
Rituximab
Donor O
Donor A-2
and no full DRC / no activity

Figure 11D



CD107a % activated Vδ2 γδ T cells summary DAR2 versus DAR8
% activated Vδ2 γδ T cells
100
90
80
70
60
50
40
30
20
10
0
ADC-XD65-r
ADC8-XD65-r
Rituximab
Donor O
Donor A-2

Figure 11E



IFNγ % activated Vδ2 γδ T cells summary DAR2 versus DAR8
% activated Vδ2 γδ T cells
100
90
80
70
60
50
40
30
20
10
0
ADC-XD65-r
ADC8-XD65-r
Rituximab
Donor O
Donor A-2

Figure 11F



TNFα % activated Vδ2 γδ T cells summary DAR2 versus DAR8
% activated Vδ2 γδ T cells
100
90
80
70
60
50
40
30
20
10
0
ADC-XD65-r
ADC8-XD65-r
Rituximab
Donor O
Donor A-2

Figure 12A



Donor AL
% dead Raji cells
100
80
60
40
20
0
+
0.000001
0.00001
0.0001
0.001
0.01
0.1
1
10
100
Concentration (µg/mL)
Donor AM
% dead Raji cells
80
60
40
20
0
+
0.000001
0.00001
0.0001
0.001
0.01
0.1
1
10
100
Concentration (µg/mL)

Figure 12A (continued)





Figure 12A (continued)






Figure 12A (continued)




Figure 12A (continued)




Figure 12B




Figure 12C




Figure 12D



Efficacy (%)
Efficacy (%)
80
60
40
20
0
Rituximab
ADC-XD18-r
ADC-XD18-i
Symbol shape
Donor R
Donor AJ
Donor AL
Donor AM
Donor AN
Donor AO
Donor AP
Donor AQ
Donor AR

Figure 13A



HMBPP
Vδ2 CD107a % activated all cell lines
% activated
100
80
60
40
20
0
Donor Q
Donor AH
Raji
HG-3
MEC-1
SU-DHL-4
SU-DHL-8

Figure 13B



Vδ2 γδ T cells - CD107a
Raji
Donor Q
% activated cells
100
80
60
40
20
0
0.000001
0.00001
0.0001
0.001
0.01
0.1
1
10
100
1000
Concentration (µg/mL)
ADC-XD18-r
ADC-XD18-i
rituximab
Vδ2 γδ T cells - CD107a
Raji
Donor AH
% activated cells
100
80
60
40
20
0
0.000001
0.00001
0.0001
0.001
0.01
0.1
1
10
100
1000
Concentration (µg/mL)
ADC-XD18-r
ADC-XD18-i
rituximab

Figure 13C



Vδ2 γδ T cells - CD107a
HG-3
Donor Q
% activated cells
100
80
60
40
20
0
0.000001
0.00001
0.0001
0.001
0.01
0.1
1
10
100
1000
Concentration (µg/mL)
ADC-XD18-r
ADC-XD18-i
rituximab
Vδ2 γδ T cells - CD107a
HG-3
Donor AH
% activated cells
100
80
60
40
20
0
0.000001
0.00001
0.0001
0.001
0.01
0.1
1
10
100
1000
Concentration (µg/mL)
ADC-XD18-r
ADC-XD18-i
rituximab

Figure 13D



Vδ2 γδ T cells - CD107a
MEC-1
Donor Q
% activated cells
100
80
60
40
20
0
0.000001
0.00001
0.0001
0.001
0.01
0.1
1
10
100
1000
Concentration (µg/mL)
ADC-XD18-r
ADC-XD18-i
rituximab
Vδ2 γδ T cells - CD107a
MEC-1
Donor AH
% activated cells
100
80
60
40
20
0
0.000001
0.00001
0.0001
0.001
0.01
0.1
1
10
100
1000
Concentration (µg/mL)
ADC-XD18-r
ADC-XD18-i
rituximab

Figure 13E



Vδ2 γδ T cells - CD107a
SU-DHL-4
Donor Q
% activated cells
100
80
60
40
20
0
0.000001
0.00001
0.0001
0.001
0.01
0.1
1
10
100
1000
Concentration (µg/mL)
ADC-XD18-r
ADC-XD18-i
rituximab
Vδ2 γδ T cells - CD107a
SU-DHL-4
Donor AH
% activated cells
100
80
60
40
20
0
0.000001
0.00001
0.0001
0.001
0.01
0.1
1
10
100
1000
Concentration (µg/mL)
ADC-XD18-r
ADC-XD18-i
rituximab

Figure 13F



Vδ2 γδ T cells - CD107a
SU-DHL-8
Donor Q
% activated cells
100
80
60
40
20
0
0.000001
0.00001
0.0001
0.001
0.01
0.1
1
10
100
1000
Concentration (µg/mL)
ADC-XD18-r
ADC-XD18-i
rituximab
Vδ2 γδ T cells - CD107a
SU-DHL-8
Donor AH
% activated cells
100
80
60
40
20
0
0.000001
0.00001
0.0001
0.001
0.01
0.1
1
10
100
1000
Concentration (µg/mL)
ADC-XD18-r
ADC-XD18-i
rituximab

Figure 14A




Figure 14B




Figure 14C




Figure 14D




Figure 14E




Figure 14F




Figure 14G




Figure 14H




Figure 14I




Figure 14J




Figure 14K




Figure 14L




Figure 15A




Figure 15B




Figure 15C




Figure 15D




Figure 15E




Figure 15F




Figure 16A




Figure 16B




Figure 16C



Vδ2 γδ T cells - TNFα
% activated cells
% activated cells
100
80
60
40
20
0
BT-474
SK-BR-3
SK-OV-3
HCT-116
Symbol shape
Donor F
Donor Y
Donor Z
Donor AU

Figure 17A




Figure 17B




Figure 17C




Figure 17D




Figure 18A



HMBPP
Vδ2 CD107a % activated all donors
% activated
100
80
60
40
20
0
Raji
MOLM-13
Donor AC
Donor AD
Donor AE
Donor AF

Figure 18B



Vδ2 γδ T cells - CD107a
Donor AC
% activated cells
100
80
60
40
20
0
0.000001
0.00001
0.0001
0.001
0.01
0.1
1
10
100
1000
Concentration (µg/mL)
ADC-XD18-r
ADC8-XD18-r
ADC16-XD59-r
ADC-XD18-i
ADC8-XD18-i
ADC16-XD59-i
rituximab
Vδ2 γδ T cells - CD107a
Donor AC
% activated cells
Concentration (µg/mL)
ADC-XD18-CD12341C
ADC10-XD18-CD12341C
ADC20-XD59-CD12341C
ADC-XD18-i41C
ADC8-XD18-i
ADC16-XD59-i
anti-CD12341C

Figure 18C



Vδ2 γδ T cells - CD107a
Donor AD
% activated cells
Concentration (µg/mL)
ADC-XD18-r
ADC8-XD18-r
ADC16-XD59-r
ADC-XD18-i
ADC8-XD18-i
ADC16-XD59-i
rituximab
Vδ2 γδ T cells - CD107a
Donor AD
% activated cells
Concentration (µg/mL)
ADC-XD18-CD123 41C
ADC10-XD18-CD123 41C
ADC20-XD59-CD123 41C
ADC-XD18-i 41C
ADC16-XD59-i
ADC16-XD59-i
anti-CD123 41C

Figure 18D



Vδ2 γδ T cells - CD107a
Donor AE
% activated cells
Concentration (µg/mL)
ADC-XD18-r
ADC8-XD18-r
ADC16-XD59-r
ADC-XD18-i
ADC8-XD18-i
ADC16-XD59-i
rituximab
Vδ2 γδ T cells - CD107a
Donor AE
% activated cells
Concentration (µg/mL)
ADC-XD18-CD123 41C
ADC10-XD18-CD123 41C
ADC20-XD59-CD123 41C
ADC-XD18-i41C
ADC8-XD18-i
ADC16-XD59-i
anti-CD123 41C

Figure 18E



Vδ2 γδ T cells - CD107a
Donor AF
% activated cells
100
80
60
40
20
0
0.000001
0.00001
0.0001
0.001
0.01
0.1
1
10
100
1000
Concentration (µg/mL)
ADC-XD18-r
ADC8-XD18-r
ADC16-XD59-r
ADC-XD18-i
ADC8-XD18-i
ADC16-XD59-i
rituximab
Vδ2 γδ T cells - CD107a
Donor AF
% activated cells
Concentration (µg/mL)
ADC-XD18-CD12341C
ADC10-XD18-CD12341C
ADC20-XD59-CD12341C
ADC-XD18-i41C
ADC8-XD18-i
ADC16-XD59-i
anti-CD12341C

Figure 18F



Vδ2 - CD107a EC50 all donors
Raji
EC50 (µg/ml)
10
1
0.1
0.01
0.001
Rituximab
ADC-XD18-r
ADC8-XD18-r
ADC16-XD59-r
Donor AC
Donor AD
Donor AE
Donor AF
Vδ2 - CD107a EC50 all donors
MOLM-13
EC50 (µg/ml)
#
100
10
1
0.1
0.01
0.001
anti-CD12341C
ADC-XD18-CD12341C
ADC10-XD18-CD12341C
ADC20-XD59-CD12341C
Donor AC
Donor AD
Donor AE
Donor AF
No full DRC/ no activity

Figure 18G




Vδ2 - CD107a % activated all donors
Raji
% activated
100
80
60
40
20
0
Rituximab
ADC-XD18-r
ADC8-XD18-r
ADC16-XD59-r
Donor AC
Donor AD
Donor AE
Donor AF
Vδ2 - CD107a % activated all donors
MOLM-13
% activated
100
80
60
40
20
0
anti-CD12341C
ADC-XD18-CD12341C
ADC10-XD18-CD12341C
ADC20-XD59-CD12341C
Donor AC
Donor AD
Donor AE
Donor AF

Figure 18H


Vδ2 - CD107a MFI all donors
Raji
MFI
8000
6000
4000
2000
0
Rituximab
ADC-XD18-r
ADC8-XD18-r
ADC16-XD59-r
Donor AC
Donor AD
Donor AE
Donor AF
Vδ2 - CD107a MFI all donors
MOLM-13
MFI
5000
4000
3000
2000
1000
0
anti-CD12341C
ADC-XD18-CD12341C
ADC10-XD18-CD12341C
ADC20-XD59-CD12341C
Donor AC
Donor AD
Donor AE
Donor AF